Treatment Strategies in Advanced Prostate Cancer/Genitourinary Malignancies: The Use of Bisphosphonates Across the Continuum

[1]  Swu-Jane Lin,et al.  Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases , 2008, Cancer.

[2]  F. Saad,et al.  Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid , 2008, Cancer.

[3]  M. Zaghloul,et al.  A controlled prospective randomized placebo-controlled trial of Zoledronic acid in bony metastatic bladder cancer patients , 2008 .

[4]  A. Breeuwsma,et al.  Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach. , 2007, The Journal of urology.

[5]  C. Morgan,et al.  The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer , 2007, Acta oncologica.

[6]  M. Kotb,et al.  Bone metastases in muscle-invasive bladder cancer. , 2006, Journal of the Egyptian National Cancer Institute.

[7]  T. Habuchi,et al.  Diagnosis of bone metastasis in men with prostate cancer by measurement of serum ICTP in combination with alkali phosphatase and prostate-specific antigen. , 2006, Clinical oncology (Royal College of Radiologists (Great Britain)).

[8]  F. Saad,et al.  Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer , 2006, Clinical Cancer Research.

[9]  F. Saad,et al.  Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers , 2005, BJU international.

[10]  I. Holen,et al.  Sequence‐ and schedule‐dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells , 2005, International journal of cancer.

[11]  R. Bukowski,et al.  Skeletal Complications in Patients with Bone Metastases from Renal Cell Carcinoma and Therapeutic Benefits of Zoledronic Acid , 2004, Clinical Cancer Research.

[12]  N. Clarke,et al.  Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer. , 2004, European urology.

[13]  G. Oades,et al.  Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation , 2004, BJU international.

[14]  F. Saad,et al.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.

[15]  M. Seibel,et al.  Markers of Bone Remodeling in Metastatic Bone Disease , 2003 .

[16]  A. Lipton,et al.  Zoledronic acid delays the onset of skeletal‐related events and progression of skeletal disease in patients with advanced renal cell carcinoma , 2003, Cancer.

[17]  G. Oades,et al.  Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. , 2003, The Journal of urology.

[18]  M. Noguchi,et al.  Serum levels of bone turnover markers parallel the results of bone scintigraphy in monitoring bone activity of prostate cancer. , 2003, Urology.

[19]  P. Clézardin,et al.  Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. , 2002, Cancer research.

[20]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[21]  F. Saad,et al.  The New Bisphosphonate, Zometa® (Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate , 2002, Cancer investigation.

[22]  R. Coleman.  Metastatic bone disease: clinical features, pathophysiology and treatment strategies. , 2001, Cancer treatment reviews.

[23]  G. Hortobagyi,et al.  Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases , 2000, Cancer.

[24]  G. Hortobagyi,et al.  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. , 1996, The New England journal of medicine.

[25]  M. Kovacs,et al.  Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. , 1996, The New England journal of medicine.

[26]  R. Vessella,et al.  Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.